Jaguar Health Compliant with Nasdaq Bid Price Rule
Rhea-AI Summary
Jaguar Health (NASDAQ:JAGX) reported that Nasdaq notified the company on May 26, 2026 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the Bid Price Rule, and its securities remain listed and traded.
Q1 2026 net revenue increased 816% year-over-year and 527% sequentially, supported by a US out-license agreement with Future Pak for Mytesi and Canalevia-CA1. Jaguar is focusing on its pivotal-stage crofelemer program for rare intestinal failure, targeting an NDA in mid-2027 and seeking a development and commercialization partner.
Positive
- Regained compliance with Nasdaq Bid Price Rule 5550(a)(2)
- Securities continue to be listed and traded on Nasdaq
- Q1 2026 net revenue increased 816% versus Q1 2025
- Q1 2026 net revenue increased 527% versus Q4 2025
- US out-license agreement with Future Pak for Mytesi and Canalevia-CA1
- NDA for crofelemer formulation targeting mid-2027
Negative
- None.
News Market Reaction – JAGX
In the May 27 session, JAGX gained 2.57%, reflecting a moderate positive market reaction. Argus tracked a peak move of +14.2% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 20 | Q1 2026 earnings | Positive | -5.5% | Massive revenue jump from licensing deal and improved operating results. |
| May 20 | Investor webcast notice | Positive | +2.8% | Announcement of webcast and conference presentation on Q1 results and updates. |
| May 19 | Clinical trial update | Positive | -9.3% | Continuation phase of pivotal pediatric MVID crofelemer trial to support NDA. |
| May 8 | Nasdaq compliance/status | Positive | +0.7% | Regained compliance with publicly held shares and extension for bid-price rule. |
| May 6 | Regulatory discussion | Positive | -6.3% | Preliminary FDA discussion on potential Breakthrough Therapy Designation. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical, financial, and listing updates have often seen mixed to negative next-day price reactions, suggesting a tendency for the stock to sell off or be volatile around good news.
Over the last month, Jaguar reported major progress across finances, pipeline, and listing status. On May 6 and May 19, it highlighted crofelemer’s development and pivotal trials for rare intestinal failure disorders. On May 8, Nasdaq granted more time to meet bid-price rules, and on May 20 the company posted a sharp Q1 2026 revenue turnaround driven by licensing. Despite these positives, several events saw negative price reactions, making today’s confirmation of full bid-price compliance a continuation of the listing-improvement narrative.
Key Terms
out-license agreement financial
pivotal-stage development program medical
nda regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
JAGX's securities continue to be listed and traded on Nasdaq
SAN FRANCISCO, CA / ACCESS Newswire / May 27, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on May 26, 2026, the Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") that Jaguar has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule").
"We are very happy that Jaguar has regained compliance with the Nasdaq listing criteria. We consider our Nasdaq listing an asset of the Company," said Lisa Conte, Jaguar's president and CEO. "As we were pleased to report on May 20, 2026, Jaguar's net revenue increased
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire